03/02/21 4:01 PMNasdaq : NEXINexImmune to Present at the 2021 Barclays Global Healthcare ConferenceNexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announcedRHEA-AIneutral
02/24/21 8:30 AMNasdaq : NEXIRapha Capital Management Announces Successful Initial Public Offering of Portfolio Company NexImmune Inc.Rapha Capital Management, LLC ( https://raphacap.com), an investment management firm located in Miami, Florida, is pleased to announce that on February 17, 2021, its portfolio company, NexImmune, Inc. ("NexImmune"), closed an upsized initial public offeringRHEA-AIneutral
02/23/21 8:00 AMNasdaq : NEXIBarer & Son Capital and Hibiscus Capital Management Announce Successful Initial Public Offering of Portfolio Company NexImmuneBarer & Son Capital, a life science venture capital fund managed by Hibiscus Capital Management, is pleased to announce that on February 17, 2021, its portfolio company, NexImmune, Inc. ("NexImmune"), closed an upsized initial public offering raisingRHEA-AIneutral
02/17/21 6:34 PMNasdaq : NEXINexImmune Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional SharesNexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body's own T cells to generate a specific, potent and durable immune response, today announced theRHEA-AIneutral
02/11/21 10:03 PMNasdaq : NEXINexImmune Announces Pricing of Upsized Initial Public OfferingNexImmune, Inc., a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body's own T cells to generate a specific, potent and durable immune response that mimics natural biology, todayRHEA-AIneutral